Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 10/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 9/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13233189 | 0.86 | RPS6KA3 (0.36) | RPS6KA3PRKCZLATS1LATS2HTR2A | |
| SCHEMBL24249190 | 0.84 | RPS6KA3 (0.42) | RPS6KA3MAP4K4MINK1TNIKLATS1 | |
| SCHEMBL13263764 | 0.82 | MAP4K4 (0.36) | MAP4K4MINK1TNIKPRKCZLATS1 | |
| SCHEMBL22793012 | 0.82 | RPS6KA3 (0.36) | RPS6KA3MAP4K4MINK1TNIKPRKCZ | |
| SCHEMBL24253585 | 0.81 | DAO (0.39) | RPS6KA3MAP4K4MINK1TNIKPRKCZ | |
| SCHEMBL22792741 | 0.78 | RPS6KA3 (0.34) | RPS6KA3MAP4K4MINK1TNIKLATS1 | |
| SCHEMBL12410896 | 0.76 | ALDH1A1 (0.48) | HTR2AHTR2CHTR2BHTT | |
| SCHEMBL19545353 | 0.76 | GLP1R (0.32) | — | |
| SCHEMBL12778210 | 0.75 | PRKCZ (0.44) | RPS6KA3PRKCZALOX5MELK | |
| SCHEMBL15423527 | 0.75 | LATS1 (0.36) | PRKCZLATS1LATS2USP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944633-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BROAD INSTITUTE, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944633-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BROAD INSTITUTE, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-04-14 | — | — | US | disclosed |
| US-9120810-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BOARD INSTITUTE, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-7750151-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | IDH1, IDH2, IDH3A | RPS6KA3 3486/4885MAP4K4 2544/4885MINK1 2019/4885 |
| US-20080280899-A1 | Inhibitors of Akt Activity | AKT1, AKT2, AKT3 | RPS6KA3 389/4885MAP4K4 189/4885MINK1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.